Molluscum contagiosum: Recent advances in pathogenic mechanisms, and new therapies

American Journal of Clinical Dermatology

Volumn 3, Issue 8, 2002, Pages 535-545

  Smith, Kathleen J ^a   Skelton, Henry ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; BETA INTERFERON; BINDING PROTEIN; CANTHARIDIN; CHEMOKINE; CIDOFOVIR; CIMETIDINE; DEPSIPEPTIDE; EFLORNITHINE; EMLA; FLUOROURACIL; IMIQUIMOD; INHIBITOR PROTEIN; LIDOCAINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PICIBANIL; PODOPHYLLOTOXIN; POTASSIUM HYDROXIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOIC ACID; SANSALVAMIDE A; SILVER NITRATE; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CARBON DIOXIDE LASER; CLINICAL TRIAL; CRYOTHERAPY; CURETTAGE; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; ELECTROCOAGULATION; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLLUSCIPOXVIRUS; MOLLUSCUM CONTAGIOSUM; PAIN; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SKIN IRRITATION; SMALLPOX VIRUS; VIRUS GENOME;

EID: 0036035393     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203080-00004     Document Type: Review

References (62)

1. Bugert JJ, Darai G. Recent advances in molluscum contagiosum virus research. Arch Virol 1997; 13: 35-47
2. Smith KJ, Yeager J, Skelton H. Molluscum contagiosum: Its clinical, histopathologic, and immunohistochemical spectrum. Int J Dermatol 1999; 38: 664-72
3. Smith KJ, Skelton HG, Frissman DM, et al. Verrucous lesion secondary to DNA viruses in patients infected with the human immunodeficiency virus in association with increased factor XIIIa-positive dermal dendritic cells. J Am Acad Dermatol 1992: 27: 943-50
4. Smith KJ, Skelton HG, Yeager J, et al. Cutaneous findings in HIV-1 positive patients: A 42-month prospective study. J Am Acad Dermatol 1994; 31: 746-54
5. Naksmura J, Arao Y, Yoshida M, et al. Molecular epidemiological study of molluscum contagiosum virus in two urban areas of western Japan by the in-gel endonuclease digestion method. Arch Virol 1992; 125: 339-45
6. Thompson CH, De-Zwart-Steffe RT, Biggs IM. Molecular epidemiology of Australian isolates of molluscum contagiosum. J Med Virol 1990; 32: 1-9
7. Thompson CH, De-Zwart-Steffe RT, Donovan B. Clinical and molecular aspects of molluscum contagiosum infection in HIV-1 positive patients. Int J STD AIDS 1992; 3: 101-6
8. Rich JD, Dickinson BP, Flaxman AB, et al. Local spread of molluscum contagiosum by electrolysis. Clin Infect Dis 1999; 28: 1171
9. Fould IS. Molluscum contagiosum: An unusual complication of tattooing [letter]. BMJ 1982; 285: 607
10. Lalani AS, Masters J, Zeng W, et al. Use of chemokine receptors by poxviruses. Science 1999; 286: 1968-71
11. Smith KJ, Skelton HG, Yeager J, et al. Molluscum contagiosum: Ultrastructural evidence for its presence in skin adjacent to clinical lesions in patients infected with human immunodeficiency virus type 1. Arch Dermatol 1992; 128: 223-7
12. Senkewich TG, Bugert JJ, Sissler J, et al. Genome sequence of a human tumorigenic poxvirus: Prediction of specific host response-evasion genes. Science 1996; 273: 813-6
13. Stine JT, Chantry D, Gray P. Virally encoded chemokines and chemokine receptors: Genetic embezzlement of host DNA. Chem Immunol 1999; 72: 161-80
14. Luttichau HR, Gerstoft J, Schwartz TW. MC148 encoded by human molluscum contagiosum poxvirus is an antagonist for human not murine CCR8. J Leukoc Biol 2001; 70: 277-82
15. Porter CD, Archard LC. Characterization and physical mapping of molluscum contagiosum virus DNA and location of a sequence capable of encoding a conserved domain of epidermal growth factor. J Gen Virol 1987; 68: 673-82
16. Wall EM, Gao J-X, Upton C. Subversion of cytokine networks by viruses. Int Rev Immunol 1998; 17: 121-55
17. Montaya M, Del Val M. Intracellular rate-limiting steps in MHC class I antigen processing. J Immunol 1999; 163: 1914-22
18. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol Today 2000; 21: 447-55
19. Fadeel B, Orrenius S, Zhivotovsky B. The most unkindest cut of all: On the multiple roles of mammalian caspases. Leukemia 2000; 14: 1514-25
20. Born TL, Morrison LA, Esteban DJ, et al. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell responses. J Immunol 2000; 164: 3246-54
21. Nizeki K, Hahimoto K. Treatment of molluscum contagiosum with silver nitrate paste. Pediatr Dermatol 1999; 16: 395-7
22. Romiti R, Ribeiro AP, Grinblat BM, et al. Treatment of molluscum contagiosum with potassium hydroxide: A clinical approach in 35 children. Pediatr Dermatol 1999; 16: 228-31
23. Hourihane J, Hodges E, Smith J, et al. Interferon alpha treatment of molluscum contagiosum in immunodeficiency patients. Arch Dis Child 1999; 80: 77-9
24. Gross G, Roussaki A, Brzoska J. Recalcitrant molluscum contagiosum in a patient with AIDS successfully treated by a combination of CO2 laser and natural interferon beta gel. Arch Derm Venereol 1998; 78: 309-10
25. Dohil M, Prendiville JS. Treatment of molluscum contagiosum with oral cimetidine: Clinical experience in 13 patients. Pediatr Dermatol 1996; 15: 71-2
26. Inui S, Asada H, Yoshikawa K. Successful treatment of molluscum contagiosum in the immunosuppressed adult with topical injection of streptococcal preparation OK-432. J Dermatol 1996; 23: 628-30
27. Syed TA, Goswani J, Ahmadpur A, et al. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% cream: A placebo-controlled, double blind study, J Dermatol 1998; 25: 309-13
28. Liota E, Smith KJ, Buckley R, et al, Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000; 4: 76-82
29. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency 1 disease. Arch Dermatol 1999; 135: 1167-9
30. Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with highly active anti-retroviral therapy (HAART) in patients with AIDS. Eur J Dermatol 1999; 9: 211-3
31. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998; 110: 734-9
32. Wagner TL, Horton VL, Carlson GL, et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 1997; 9: 837-45
33. Tomai MA, Birmachu W, Case MT, et al. Imiquimod: In vivo in vitro characteristics and toxicology. In: Aly R, Beautner KR, Maibach H, editors. Cutaneous Infection and Therapy. New York: Marcel Dekker Inc, 1997: 405-15
34. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995; 58: 365-72
35. Wagner TL, Ahone CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191: 10-9
36. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-41
37. Burns RP, Ferbel B, Tomai M, et al. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000; 94: 13-23
38. Miller RL, Gerster JF, Owens ML, et al. Imiquimod applied topically: A novel immune response modifier and new class of drug. Int J Immunopharmacol 1999: 21: 1-14
39. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002-7
40. Urdiales JL, Morata P, Nunez I, et al. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996; 102: 31-7
41. Hwang Y, Rowley D, Rhodes D, et al. Mechanism of inhibition of a Poxvirus topoisomerase by the marine natural product sansalvamide A. Mol Pharmacol 1999; 55: 1049-53
42. De Clercq E. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox-, and adenovirus) infections. Verh K Acad Geneeskd Belg 1996; 58: 19-47
43. De Clercq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 1997; 40: 295-303
44. Safrin S, Cherrington J, Jaffe HS. Clinical uses of cidofovir. Rev Med Virol 1997; 7: 145-56
45. Zabawski EJ, Cockerell CJ. Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol 1999; 16: 414-5
46. Toro JR, Wood LV, Patel NK, et al. Topical cidofovir: A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000; 136: 983-5
47. Meadows KP, Tyring SK, Pavia AT, et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients with cidofovir. Arch Dermatol 1997; 133: 987-90
48. Scolaro MJ, Gordon P. Electron beam therapy for AIDS related molluscum contagiosum lesions: Preliminary experience. Radiology 1999; 210: 479-82
49. Smetana Z, Malik Z, Orenstein A, et al. Treatment of viral infections with 5-aminolevulinic acid and light. Lasers Surg Med 1997; 21: 351-8
50. Arany I, Tyring SK, Brysk MM, et al. Correlation between pretreatment of interferon response genes and clinical responses to an immune response modifier (imiquimod) in genital warts. Antimicrob Agents Chemother 2000; 44: 1869-73
51. Matikaninen S, Lehtonen A, Sareneva T, et al. Regulation of IRF and STAT gene expression by retinoic acid. Leuk Lymphoma 1998; 30: 63-71
52. Chelfbi-Alix MK, Pelicano L. Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. Leukemia 1999; 13: 167-74
53. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27: 561-4
54. Smith KJ, Germain M, Skelton H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, sulindac: Potential applications for this combination of immunotherapy. Dermatol Surg 2001; 27: 143-6
55. Pedoushek J, Smith KJ. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1 positive man. Arch Dermatol 2001; 137: 14-6
56. Manni A, Trout D, Verdeame MF, et al. Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture. Breast Cancer Res Treat 2001; 68: 139-46
57. Pfeffer LM, Yang CH, Pfeffer SR, et al. Inhibition of ornithine decarboxylase induces STAT3 tyrosine phosphorylation and DNA binding in IEC-6 cells. Am J Physiol Cell Physiol 2000; 278: C331-5
58. Gazzaniga S, Bravo A, Goldszmid SR, et al. Inflammatory changes after cryosurgery induced necrosis in human melanoma xenografted in nude mice. J Invest Dermatol 2001; 116: 664-71
59. Razhev SV, Stepanenko SM, Geraskin AV, et al. Experience in the use of EMLA in analgesia of children operated on in one-day surgical hospital. Anesteziol Reanimatol 1999; 4: 52-3
60. Ronnerfalt L, Fransson J, Wahlgren CF. EMLA cream provides rapid pain relief for the curettage of molluscum contagiosum in children with atopic dermatitis without causing serious application site reactions. Pediatr Dermatol 1998; 15: 309-12
61. Rincon E, Baker RL, Iglesias AJ, et al. CNS toxicity after topical application of EMLA cream on a toddler with molluscum contagiosum. Pediatr Emerg Care 2000; 16: 252-4
62. Bucalo BD, Mirikitani EJ, Moy RL. Comparison of skin anesthetic effect of liposomal lidocaine, nonliposomal lidocaine, and EMLA using 30-minute application time. Dermatol Surg 1998; 24: 537-41